|
|
Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.
According to the FDA, adverse drug events harmed or killed approximately 1,200,000 people in the United States in the year 2015.
This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.
On average, the stomach produces 2 L of hydrochloric acid per day.
In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.